Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06436183 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Apollo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT06436183 is a Phase 2 study that has completed, run by Apollo Therapeutics. The registered enrollment target is 62 participants.
The verdict
NCT06436183, a Phase 2 study, has completed, sponsored by Apollo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Interventions
- DRUG Placebo
- DRUG Camoteskimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2025-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06436183
The ClinicalTrials.gov registry entry for NCT06436183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apollo Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06436183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06436183 about?
NCT06436183 is a clinical study titled "A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis". This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
What is the current status of trial NCT06436183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2024-05-01. Estimated completion is 2025-08-12.
What interventions are being tested in trial NCT06436183?
The interventions under investigation include: Placebo (DRUG), Camoteskimab (DRUG).
Who is sponsoring clinical trial NCT06436183?
This trial is sponsored by Apollo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.